Johnson & Johnson has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke.
After the acquisition, Micrus Endovascular will operate under Codman Neurovascular, a business unit of Codman & Shurtleff, the global neurosurgery device company of the DePuy Family of Companies within Johnson & Johnson.
Codman Neurovascular and Micrus offer complementary products and technologies for treating cerebral aneurysms, which can lead to stroke.
The Codman Neurovascular portfolio includes bare platinum coils, vascular reconstruction devices (VRDs) and access devices, and the Micrus portfolio includes enhanced bioactive coil devices, balloon catheters, delivery systems and stents for the treatment of intracranial stenosis.
Codman & Shurtleff worldwide president Laxmin Laxminarain said that Codman and Micrus are coming together to create one of the broadest portfolios and one of the deepest pipelines in the neurovascular industry.
“There are significant unmet needs in the treatment of neurovascular disease, and our hope is that by bringing these companies together, we can fuel rapid and meaningful innovation that further improves patient care, outcomes and access to treatment,” Laxminarain said.